Gunjan Shah
Memorial Sloan Kettering Cancer Center · Veeda Clinical Research, India
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gunjan Shah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06679829 · A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantMemorial Sloan Kettering Cancer Center · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT05393804 · A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantMemorial Sloan Kettering Cancer Center · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT05130827 · Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Memorial Sloan Kettering Cancer Center · active not recruiting · Multiple Myeloma · principal investigator
- Ph1NCT05081479 · A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for LymphomaMemorial Sloan Kettering Cancer Center · active not recruiting · Lymphoma · principal investigator
- Ph1/Ph2NCT04635735 · Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaMemorial Sloan Kettering Cancer Center · terminated · Relapsed/Refractory Multiple Myeloma · principal investigator
- Ph2NCT03556332 · A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationMemorial Sloan Kettering Cancer Center · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT03315026 · Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisMemorial Sloan Kettering Cancer Center · active not recruiting · Multiple Myeloma, AL Amyloidosis · principal investigator
- Ph1NCT01581788 · Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed ConditionsDr. Reddy's Laboratories Limited, India · completed · Healthy · principal investigator
- Ph1NCT01581775 · Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting ConditionsDr. Reddy's Laboratories Limited, India · completed · Healthy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:52 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- GPRC5D-Targeted CAR T Cells for Myeloma.N Engl J Med · 2022385 citationsRCR 25.1
- 105 citationsRCR 5.2
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.Lancet Haematol · 202189 citationsRCR 4.8
- Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.Biol Blood Marrow Transplant · 201839 citationsRCR 1.4
- 30 citationsRCR 6.1
- Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.Clin Lymphoma Myeloma Leuk · 202018 citationsRCR 0.7
- 14 citationsRCR 0.7
- Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.Biol Blood Marrow Transplant · 202010 citationsRCR 0.6
- Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance.Clin Cancer Res · 20253 citationsRCR 0.5